Report Highlights

HPV in the United States: Market Overview

The U.S. HPV market is unusual because it combines a single-supplier vaccine franchise with a highly competitive diagnostics segment. Merck's Gardasil 9 dominates prophylactic vaccination, while Roche, Hologic, Becton Dickinson and Abbott compete in high-risk HPV DNA testing. Valued at USD 5.1 billion in 2024, the market sits well above the global norm, where vaccine volumes in lower-income countries depend largely on Gavi funding rather than commercial payers.

Structurally, American demand is shaped by payers rather than patients. Commercially insured patients receive HPV vaccination with no cost-sharing under Section 2713 of the Affordable Care Act, while the Vaccines for Children program purchases roughly half of pediatric doses at discounted CDC contract prices. This dual channel compresses vaccine margins and pushes manufacturers toward value-based pricing negotiations with large health systems and state immunization registries.

Growth Drivers in the U.S. HPV Market

Three country-specific drivers sustain demand. First, the Advisory Committee on Immunization Practices' 2016 move to a two-dose schedule for adolescents aged 9 to 14 lowered the cost per course and widened uptake in pediatric practices. Second, the FDA's 2025 clearance of at-home self-collection for cervical screening opens testing to women who avoid gynecology appointments, a group the CDC identifies as persistently under-screened.

Third, disease burden keeps expanding the addressable population. The CDC estimates that more than 40,000 HPV-associated cancers are diagnosed annually in the United States, including oropharyngeal cancers rising among men. ACIP's routine recommendation for males aged 11 to 12, combined with its shared decision-making extension to adults aged 27 to 45, broadens vaccine eligibility beyond the traditional female adolescent cohort.

Market Restraints and Entry Barriers

Regulatory and reimbursement hurdles are the most prominent barriers. Vaccines require an FDA Biologics License Application and sustained ACIP recommendation before insurers must cover them, so a new entrant faces a multi-year evidence cycle before reaching payers. Diagnostic entrants need either FDA 510(k) or premarket approval, and the FDA's laboratory-developed test rule was vacated in March 2025, leaving CLIA certification as the primary laboratory oversight layer.

Incumbent advantages and vaccine hesitancy compound these barriers. Merck's installed base, combined with Vaccines for Children contract tiers, leaves little room for price-led share capture. Persistent parental hesitancy and state-level exemption policies also cap adolescent coverage, while distribution complexity across retail pharmacies, public clinics and reference laboratories raises customer acquisition costs for smaller players.

Market Opportunities in the United States

Self-collection testing represents the most immediate entry opportunity. With roughly 60 million American women in the core cervical screening age band, underscreened populations in rural counties and Medicaid expansion states offer a large addressable base. Entrants that pair at-home kits with telehealth ordering and laboratory processing can capture patients who currently miss screening entirely.

Adjacent opportunities lie in male and anal cancer screening. Anal cancer screening for high-risk adults, supported by HRSA women's preventive guidelines and specialty clinic referral networks, remains underdeveloped relative to cervical programs. NIS-Teen data show only about 63 percent of U.S. adolescents completing the HPV vaccine series, leaving meaningful catch-up uptake in pediatric practices and pharmacy vaccination programs.

Market at a Glance

Leading Market Participants

• Merck & Co.
• GlaxoSmithKline
• Roche Diagnostics
• Hologic
• Becton Dickinson
• Abbott Laboratories
• Qiagen
• Quest Diagnostics
• Labcorp
• Teal Health

Regulatory and Policy Environment

Vaccine oversight runs through the FDA's Center for Biologics Evaluation and Research, which licenses products under the Public Health Service Act, and the CDC's ACIP, which sets recommendations that trigger coverage under the Affordable Care Act. HPV vaccines are also covered under the National Vaccine Injury Compensation Program, which shifts liability claims away from manufacturers. Diagnostics fall under FDA device rules and CLIA certification administered by CMS, with laboratories generally renewing certificates on a multi-year cycle.

Public funding shapes access at scale. The Vaccines for Children program supplies vaccines to eligible children through federal contracts, and Section 317 grants support state immunization infrastructure. Medicaid matching rates of at least 50 percent cover HPV services for enrollees, while Medicare covers cervical cancer screening under Part B. Device clearance timelines run roughly 90 days for 510(k) submissions and about 180 days for premarket review.

Long-Term Outlook for U.S. HPV

By 2032, the U.S. HPV market will be defined more by diagnostics growth than vaccine expansion. Gardasil 9 volumes should plateau near current adolescent coverage, while self-collection testing and expanded adult screening lift diagnostics revenue faster. Roche, Hologic and Abbott will compete on workflow integration with pharmacy, telehealth and primary-care platforms.

Reimbursement and pricing will set the competitive order. Payers will reward cost-effective single-visit screening, while CMS coverage rules keep primary-care reimbursement fixed across cycles. Entrants that secure contracts with Quest Diagnostics, Labcorp and national retail pharmacy chains will hold the strongest position as the market approaches USD 7.9 billion in 2032.